SNCA and Parkinson disease: Based on the in silico inference and previous preliminary findings, we conducted the experiments to validate the alteration of UBA52 in PD-specific pathological markers in both sporadic cellular and rat experimental models and SNCA C57BL/6J-Tg (Th-SNCA*A30P*A53T) 39Eric/J transgenic mice.